GSK Pharma Shares Surge 9% on Stellar Q3 Performance

GlaxoSmithKline Pharmaceuticals (GLAX.NS) shares jumped 9% in pre-open trade on February 17, 2025, following the company's impressive Q3 FY25 results. The pharmaceutical giant reported a 402% year-on-year increase in consolidated net profit to ₹228.58 crore, up from ₹45.49 crore in Q3 FY24. Revenue from operations rose 17.5% to ₹946.36 crore, driven by strong performance across key product portfolios. GSK Pharma's flagship brands, including Augmentin and Ceftum, gained market share, while its innovative respiratory portfolio led by Nucala and Trelegy achieved robust growth. The company also maintained its leadership in the self-pay private market for paediatric vaccines.

 

Sources: CNBC TV18, Business Standard, Financial Express